The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete.

UNI	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D Notice of Exempt Offering of Securities			OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00
	Nonce of Exempt			
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	X None	Entity Type	
0001492422 Name of Issuer Apellis Pharmaceuticals, Inc. Jurisdiction of Incorporation/O DELAWARE Year of Incorporation/Organiza X Over Five Years Ago Within Last Five Years (Spectrum) Yet to Be Formed	ation		X Corporation Limited Partners Limited Liability General Partner Business Trust Other (Specify)	Company ship
	and Contract Information			
2. Principal Place of Busines	is and Contact Information			
Name of Issuer Apellis Pharmaceuticals, Inc. Street Address 1 6400 WESTWIND WAY City	State/Province/Country	Street Address 2 SUITE A ZIP/PostalCode	Phone Number of	Issuer
CRESTWOOD	KENTUCKY	40014	502-241-4114	
3. Related Persons				
Last Name Francois Street Address 1	First Name Cedric Street Address 2		Middle Name	
6400 Westwind Way City Crestwood	Suite A State/Province/Cour KENTUCKY	ntry	ZIP/PostalCode 40014	
Relationship: X Executive Of Clarification of Response (if Net				
· · ·				
Last Name Deschatelets Street Address 1 6400 Westwind Way	First Name Pascal Street Address 2 Suite A		Middle Name	
City Crestwood Relationship: X Executive Of	State/Province/Cour KENTUCKY	ntry	ZIP/PostalCode 40014	
Clarification of Response (if Network)	ecessary):			
Last Name	First Name		Middle Name	
Dunlop Street Address 1 7910 Woodmont Avenue	A. Street Address 2 Suite 1210		Sinclair	

City State/Province/Country		ZIP/PostalCode		
Bethesda	MARYLAND	20814		
Relationship: Executive Offi	cer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
Machiels	Alec			
Street Address 1	Street Address 2			
6400 Westwind Way	Suite A			
City	State/Province/Country	ZIP/PostalCode		
Crestwood	KENTUCKY	40014		
Relationship: Executive Offi	cer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
Chan	Gerald			
Street Address 1	Street Address 2			
1188 Centre Street				
City	State/Province/Country	ZIP/PostalCode		
Newton	MASSACHUSETTS	02459		
Relationship: Executive Offi	cer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
O'Brien	Stephanie			
Street Address 1	Street Address 2			
1188 Centre Street				
City	State/Province/Country	ZIP/PostalCode		
Newton	MASSACHUSETTS	02459		
Relationship: Executive Offi	cer X Director Promoter			
Clarification of Response (if Neo	cessary):			
4. Industry Group				

Agriculture	Health Care	
Banking & Financial Services	X Biotechnology	Retailing
Commercial Banking	Health Insurance	Restaurants
Insurance	Hospitals & Physicians	Technology
Investment Banking	Pharmaceuticals	Computers
Pooled Investment Fund	Other Health Care	Telecommunications
Is the issuer registered as	Manufacturing	Other Technology
an investment company under the Investment Company	Real Estate	Travel
Act of 1940?	Commercial	Airlines & Airports
Yes No	Construction	Lodging & Conventions
Other Banking & Financial Services	REITS & Finance	Tourism & Travel Services
Business Services	Residential	Other Travel
Energy		
Coal Mining	Other Real Estate	Other
Electric Utilities		
Energy Conservation		
Environmental Services		

5. Issuer Size

Oil & Gas

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues	[No Aggregate Net Asset Value
X \$1 - \$1,000,000	[\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	[\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	[\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000	[Over \$100,000,000
Decline to Disclose	[Decline to Disclose
Not Applicable	[Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii)			
Rule 505	Section 3(c)(4)	Section 3(c)(12)	
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)	
Rule 506(c)		Section 3(0)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

X	New Notice	Date of First Sale 2014-12-05	First Sale Yet to Occur
	Amendment		

F

Duration of Offering		
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or O Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combina merger, acquisition or exchange offer?	ition transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$10,000	USD	
12. Sales Compensation		
Recipient (Associated) Broker or Dealer X None	Recipient CRD Number X None (Associated) Broker or Dealer CRD Number X None	
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$21,500,000 USD or Indefinite		
Total Amount Sold \$6,000,000 USD		
Total Remaining to be Sold \$15,500,000 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread	y have invested in the offering.	
Regardless of whether securities in the offering have been or r investors, enter the total number of investors who already hav		1
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	ot known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:

 (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Apellis Pharmaceuticals, Inc.	Cedric Francois	Cedric Francois	Chief Executive Officer	2014-12-17

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D. States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.